Hvivo raises full year sales and earnings guidance

The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent

Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and profit guidance for 2023 after reporting double-digit growth for the first six months of the year.

On Tuesday, the Dublin-headquartered company reported a 52 per cent increase in half year sales to £27.3 million (€31.8 million) on the back of new contract wins to run clinical trials and human challenge studies on behalf of large pharma and biotech companies.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO